TEC24-Hematology and Gene Therapy Research Group: HemaTerGe
Advanced Therapies and Biomedical Technologies / IBS-TEC24 / Consolidated
The overall objective of HemaTerGe is to deepen the biological and clinical knowledge of haematological diseases in order to improve their prognosis and generate efficient, safe and cost-effective advanced therapy medicines (ATMP) for the treatment of haematological diseases, cancer and monogenetic diseases. This objective requires collaboration and coordination between scientists, physicians and other stakeholders (pharmaceutical companies, regulators, patients, etc.) to provide regulatory preclinical data and facilitate their application to the national health system. In particular, the new HemaTerGe group seeks to advance the treatment of haematological diseases, with a special focus on cancer and monogenetic diseases. To this end, the group has basic researchers who are experts in gene therapy and genome editing and clinical researchers with extensive experience in research into different haematological diseases and in conducting clinical trials.
Research lines
- Preclinical research into advanced therapies for the treatment of cancer.
- Preclinical research into advanced therapies for the treatment of monogenic diseases.
- Proposals for “first-in-human” clinical trials in Advanced Therapies.
- Hematopoietic Transplantation and Cell Therapy
- Lymphoid and Myeloid Neoplasms
- Coagulation and Hemostasis
- Psycho-emotional sphere and quality of life.
Research networks
- REDTERAV - Advanced Therapies
- CA21113 - Genome Editing to Treat Humans Diseases (GenE-Humdi)
Keywords
CAR-T, 2. Lymphoid and Myeloid Neoplasms, Cell Therapy, monogenic diseases
ALBA GAMEZ GAMEZ
Antonio Matilla Serrano
MARIA TRISTAN MANZANO
Alberto Tagliaferro Quinonero
JON RUIZ DE FRANCISCO
ANTONIO ROMERO AGUILAR
IRIS RAMOS HERNANDEZ
KRISTINA PAVLOVIC PAVLOVIC
AMANDA NUÑEZ GARCIA
LUCIA MORATALLA LOPEZ
BEATRIZ MESA SIMON
Elena Masana Flowers
ELISA LOPEZ FERNANDEZ
MANUEL JOURNEY CHACON
ANA HINCKLEY BONED
FRANCISCA HERNANDEZ MOHEDO
PEDRO ANTONIO GONZALEZ SIERRA
PABLO GALLINDO NAVARRO
LAURA TRAINS UREÑA
Alicia Delgado Garcia
LINARES FERNANDEZ LONELINESS
Antonio Jesus Cruz Diaz
Marina Cortijo Gutierrez
Maria Esther Clavero Sanchez
Carlos Blanco Benitez
JOSE MANUEL DOOR DOOR
FRANCISCO JAVIER MOLINA ESTEVEZ
PILAR MUÑOZ FERNANDEZ
VERONICA AYLLON CASES
FRANCISCO MARTIN MOLINA
Donor insertion into CX3CR1 allows epigenetic modulation of a constitutive promoter on hematopoietic stem cells and its activation upon myeloid differentiation
NUCLEIC ACIDS RESEARCH, 2025;
FI: 13,1; D1
Advanced delivery systems for gene editing: A comprehensive review from the GenE-HumDi COST Action Working Group
MOLECULAR THERAPY-NUCLEIC ACIDS, 2025;
FI: 6,1; Q1
Proceedings of the second annual meeting of GenE-HumDi (COST Action 21113)
FRONTIERS IN GENOME EDITING, 2025;
FI: 4,4; Q1
Regulatory Strategies for Accelerating the Translation of Gene Therapies to Clinical Practice: Focus on GMO Considerations
HUMAN GENE THERAPY, 2025;
FI: 4; Q1
Exploring miR-21 Knock-Out Using CRISPR/Cas as a Treatment for Lung Cancer
GENES, 2025;
FI: 2,8; Q2
UMBRELLA-SUMMA LEGACY (Unified platform for a Better integRal Evaluation of myeLodyspLastic syndromes in spAin)
Funder: CARLOS III HEALTH INSTITUTE - FEDER
File number: PMP24/00025
Execution time: 19/11/2025 - 31/12/2026
IP: FRANCISCA HERNANDEZ MOHEDO
RICORS Advanced therapies: TERAV+ NETWORK
Funder: Carlos III Health Institute - PRTR
File number: RD24 / 0014/0005
Execution time: 01/01/2025 - 31/12/2027
IP: FRANCISCO MARTIN MOLINA
Lymphocyte engineering for the generation of universal and inducible CAR-T cells for immunotherapy of refractory lymphomas
Funder: HEALTH AND CONSUMPTION COUNCIL
File number: PI-0236-2024
Execution time: 28/11/2024 - 29/11/2027
IP: FRANCISCO MARTIN MOLINA
Overcoming limitations to strengthen and enhance gene therapy strategies for the treatment of Pompe disease.
Funder: CARLOS III HEALTH INSTITUTE - FEDER
File number: PI24 / 00216
Execution time: 01/01/2025 - 31/12/2027
IP: Pilar Muñoz Fernandez
Development of inducible 4th-generation CAR-T cells for the treatment of solid tumors
Funder: CARLOS III HEALTH INSTITUTE - FEDER
File number: PI24 / 00888
Execution time: 01/01/2025 - 31/12/2027
IP: FRANCISCO MARTIN MOLINA
Retrospective observational study to characterize patients with chronic lymphocytic leukemia treated with zanubrutinib in routine clinical practice in Spain. ReaLLCZa.
Financier: BEONE MEDICINES ESP, SLU,
Test type: OBSERVATIONAL STUDY WITH MEDICINES
Execution time: 06/03/2025 - 30/12/2025
IP: JOSE M PUERTA PUERTA
Patient and hematologist preferences regarding CLL treatment after BTKi: a discreet choice experiment in Spain. LIL-2024-177
Financier: LILLY, SA
Test type: OBSERVATIONAL STUDY WITH MEDICINES
Execution time: 14/11/2025 - 30/12/2026
IP: JOSE M PUERTA PUERTA
MAGNETISMM-16: Post-authorization safety study (PASS), international, multicenter, non-interventional, to evaluate the effectiveness and safety of elranatamab in patients with relapsed/resistant multiple myeloma (RRMM) treated in real-life (RW) settings.
Funder: PFIZER INC
Test type: OBSERVATIONAL STUDY WITH MEDICINES
Execution time: 14/02/2025 - 30/12/2029
IP: MARIA ESTHER CLAVERO SANCHEZ
A multicenter, prospective study of current standard-of-care treatments in real-world settings for patients with relapsed and/or refractory multiple myeloma. MoMMent
Funder: JANSSEN-CILAG INTERNATIONAL NV
Test type: OBSERVATIONAL STUDY WITH MEDICINES
Execution time: 01/04/2025 - 30/06/2028
IP: MARIA ESTHER CLAVERO SANCHEZ
Retrospective, multinational study of clinical outcomes in patients with relapsed/refractory multiple myeloma treated with T-cell redirecting agents outside of clinical trials. (REALITEC Study)
Financier: JANSSEN PHARMACEUTICA NV
Test type: OBSERVATIONAL STUDY WITH MEDICINES
Execution time: 31/03/2025 - 30/04/2026
IP: MARIA ESTHER CLAVERO SANCHEZ
Retrospective, multicenter, multinational clinical review to describe the use of maribavir and its efficacy in patients with post-transplant cytomegalovirus infection/disease – ARISE.
Funder: TAKEDA PHARMACEUTICALS INTERNATIONAL AG
Test type: OBSERVATIONAL STUDY WITH MEDICINES
Execution time: 08/05/2025 - 30/08/2025
PI: PEDRO ANTONIO GONZALEZ SIERRA
A phase 3, randomized, open-label study of axatilimab versus best available therapy in participants with chronic graft-versus-host disease after at least 2 prior lines of systemic therapy.
Financer: INCYTE CORPORATION
Type of test: CLINICAL TRIAL WITH DRUGS
Execution time: 09/06/2025 - 30/01/2033
PI: MANUEL JURADO CHACON
A phase 3, randomized, open-label, multicenter study comparing the efficacy and safety of BMS-986393, a GPRC5D-targeted CAR-T cell therapy, versus standard regimens in adult subjects with lenalidomide-resistant relapsed or refractory multiple myeloma. QUINTESSENTIAL-2
Funder: CELGENE CORPORATION
Type of test: CLINICAL TRIAL WITH DRUGS
Execution time: 03/12/2025 - 30/10/2032
IP: MARIA ESTHER CLAVERO SANCHEZ
Multi-phase, dose-escalation study followed by an open-label, randomized, crossover study of oral ASTX030 (combined with cedazuridine and azacitidine) versus subcutaneous azacitidine in patients with myelodysplastic syndromes (MDS), chronic myelomonocytic leukemia (CMML), or acute myeloid leukemia (AML).
Funder: TAIHO ONCOLOGY, INC.
Type of test: CLINICAL TRIAL WITH DRUGS
Execution time: 07/08/2025 - 30/12/2028
PI: PEDRO ANTONIO GONZALEZ SIERRA
A phase III, multicenter, randomized, open-label study comparing the efficacy and safety of golcadomide in combination with rituximab (Golca + R) versus the investigator's choice of therapy in participants with relapsed/refractory follicular lymphoma who have received at least one prior line of systemic therapy (GOLSEEK-4)
Funder: CELGENE CORPORATION
Type of test: CLINICAL TRIAL WITH DRUGS
Execution time: 09/04/2025 - 30/07/2032
IP: JOSE M PUERTA PUERTA
Efficacy of asciminib as a single agent or in combination with nilotinib in the treatment of chronic myeloid leukemia at diagnosis. Pearl Study
Funder: SPANISH GROUP FOR CHRONIC MYELOID LEUKEMIA (GELMC)
Type of test: CLINICAL TRIAL WITH DRUGS
Execution time: 07/02/2025 - 07/02/2026
IP: JOSE M PUERTA PUERTA
Glofitamab combined with pirtobrutinib in patients with relapsed or refractory mantle cell lymphoma followed by extension in treatment-naïve patients.
Funder: KLINIKUM DER UNIVERSITAT MUNCHEN-GR
Type of test: CLINICAL TRIAL WITH DRUGS
Execution time: 02/07/2025 - 30/05/2032
IP: JOSE M PUERTA PUERTA
A phase 1, open-label, dose-escalation and expansion study to evaluate the safety, tolerability, and clinical activity of SNDX-5613 in combination with intensive chemotherapy in participants with newly diagnosed acute myeloid leukemias with alterations in the lysine methyltransferase 2A (KMT2A/MLL), nucleophosmin 1 (NPM1), and nucleoporin 98 (NUP98) genes.
Funder: SYNDAX PHARMACEUTICALS, INC
Type of test: CLINICAL TRIAL WITH DRUGS
Execution time: 18/02/2025 - 30/07/2029
PI: PEDRO ANTONIO GONZALEZ SIERRA
Spanish Registry of Primary Immune Thrombocytopenia and other immune thrombocytopenias.
Funder: Spanish Foundation for Hematology and Hemotherapy
Test type: OBSERVATIONAL STUDY WITH MEDICINES
Execution time: 19/12/24 - 31/12/34
IP: LAURA ENTRENA UREÑA
Impact of CMV-specific immune reconstitution at the end of Letermovir prophylaxis on the development of late cytomegalovirus infection in patients with hematopoietic progenitor cell transplantation (INMUNOEND Study).
Funder: FIBICO. BIOMEDICAL RESEARCH FOUNDATION OF CÓRDOBA
Test type: OBSERVATIONAL STUDY WITH MEDICINES
Execution time: 25/11/24 - 31/12/27
PI: PEDRO ANTONIO GONZALEZ SIERRA
Analysis of patients with chronic lymphocytic leukemia (CLL) who discontinue BTK inhibitor monotherapy without disease progression.
Funder: Spanish Chronic Lymphocytic Leukemia Group
Test type: OBSERVATIONAL STUDY WITH MEDICINES
Execution time: 30/10/24 - 28/02/25
IP: JOSE M PUERTA PUERTA
Cross-sectional study to evaluate perceptions of physical activity in patients with hemophilia A treated with emicizumab. HEMO-ACT STUDY
Financier: ROCHE FARMA, SA
Test type: OBSERVATIONAL STUDY WITH MEDICINES
Execution time: 23/04/2024 - 30/03/2025
IP: LAURA ENTRENA UREÑA
A phase II, open-label, randomized, multicenter trial to evaluate the safety and efficacy of axatilimab in combination with ruxolitinib in participants with newly diagnosed chronic graft-versus-host disease.
Financer: INCYTE CORPORATION
Type of test: CLINICAL TRIAL WITH DRUGS
Execution time: 04/07/2024 - 30/09/2028
PI: MANUEL JURADO CHACON
Phase II dose-finding and interception study of linvoseltamab in patients with high-risk monoclonal gammopathy of undetermined extent or non-high-risk asymptomatic multiple myeloma.
Funder: ICON CLINICAL RESEARCH LTD
Type of test: CLINICAL TRIAL WITH DRUGS
Execution time: 22/08/2024 - 26/06/2032
IP: MARIA ESTHER CLAVERO SANCHEZ
Phase II study of linvoseltamab in patients with asymptomatic multiple myeloma at high risk of progression to multiple myeloma.
Funder: ICON CLINICAL RESEARCH LTD
Type of test: CLINICAL TRIAL WITH DRUGS
Execution time: 29/01/2024 - 29/08/2032
IP: MARIA ESTHER CLAVERO SANCHEZ
A phase IIb, multicenter, randomized, double-blind trial evaluating combined oral fecal microbiotherapy MaaT033 for preventing complications of allogeneic hematopoietic stem cell transplantation. (PHOEBUS Trial)
Funder: ICON CLINICAL RESEARCH LTD
Type of test: CLINICAL TRIAL WITH DRUGS
Execution time: 21/02/2024 - 30/06/2027
PI: MANUEL JURADO CHACON
